Trigeminal neuralgia is a condition that causes a sensation of pain similar to an electric shock on one side of the face. This sensation is caused by alterations of the trigeminal nerve that transmits the information from the face to the brain.
There are several therapeutic options for this type of neuralgia. However, they usually have unwanted side effects and the pain reappears in most cases. The Neurological Diseases and Neurogenetics research group of IDIBELL and the Bellvitge University Hospital has carried out a study to evaluate the effectiveness and safety of two intravenous drugs against trigeminal neuralgia, lacosamide, and phenytoin. Intravenous administration usually prevails in the treatment of acute crises, since it provides a faster action and oral administration is usually counterproductive due to pain.
The study results published in Cephalalgia demonstrate that the two drugs are effective and safe for the acute treatment of trigeminal neuralgia. The retrospective study of 144 cases indicates that more than 70% presented pain relief with both drugs. However, the group of people treated with lacosamide had fewer adverse effects than the group treated with phenytoin. Also, lacosamide showed a lower rate of hospital readmission and a longer duration of relief.
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
A new technique allows the design of solid materia...
En nuestro post hablamos sobre este interesante tipo de célula del...
This is the first study to provide scientific evidence for faster and ...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory